Tuesday, February 28, 2017 8:57:52 AM
52 minutes ago - DJNF
SAN DIEGO, Feb. 28, 2017 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, today announced that its product candidate Resolaris(TM) was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of limb girdle muscular dystrophy (LGMD) patients.
"Receiving Orphan Drug Designation for the treatment of all types of LGMD patients with Resolaris is an important step in our overall process of bringing our first Physiocrine-based product candidate to the market to treat patients," said John Mendlein, CEO of aTyr Pharma. "This designation follows our recently granted Fast Track designation and our promising signals of clinical activity in a LGMD sub-type (LGMD2B). We are excited to continue the development of Resolaris to treat patients with rare myopathies with an immune component who currently have limited or no therapeutic treatment options."
The FDA's Orphan Drug Designation program is intended to advance the development of products which demonstrate promise in diagnosing or treating rare conditions that affect fewer than 200,000 people in the U.S. Sponsors developing orphan-designated products are eligible for incentives under the program, including seven years of market exclusivity following FDA approval, waiver or partial payment of application fees, and certain tax credits.
DUKE BASKETBALL and NOTRE DAME FOOTBALL
Recent LIFE News
- Evolve Announces September 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 09/18/2024 09:21:00 PM
- Evolve Announces August 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 08/21/2024 09:00:00 PM
- Evolve Announces July 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 07/22/2024 09:00:00 PM
- Evolve Announces June 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 06/19/2024 10:00:00 PM
- Evolve Announces May 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 05/21/2024 09:00:00 PM
- Evolve Announces April 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 04/17/2024 09:00:00 PM
- Evolve Announces March 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 03/20/2024 09:05:00 PM
- Evolve Announces February 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 02/21/2024 10:39:00 PM
- Evolve Announces January 2024 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 01/23/2024 10:34:00 PM
- Evolve Announces Final 2023 Annual Distributions for Certain Evolve Funds • PR Newswire (Canada) • 12/30/2023 03:48:00 AM
- Evolve Announces December 2023 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 12/19/2023 10:00:00 PM
- Evolve Announces Estimated Annual Distributions for Certain Evolve Funds • PR Newswire (Canada) • 11/29/2023 01:13:00 AM
- Evolve Announces October 2023 Distributions for Certain Evolve Funds • PR Newswire (Canada) • 10/23/2023 09:30:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM